Cardiovascular disease (CVD) is one of the most common chronic diseases in older populations, which has been increasing in line with rising overweight and obesity levels in recent years. Dietary intake is a major modifiable risk factor for CVD, and one such recommendation is to increase the intake of essential (omega-3) polyunsaturated fats in our diets, for example by consuming more oily fish. We know, however, from large population level dietary surveys, that many individuals within the United Kingdom (UK) population are not consuming enough oily fish. Therefore, alternative dietary sources of omega-3 polyunsaturated fats are required to help meet consumer needs. Quinoa is a traditional Andean seed crop consumed in a similar fashion to staple cereal grains in Europe, and the popularity of quinoa has been growing worldwide because of its nutritional content and perceived healthiness. Quinoa contains a small amount of fat, but the ratio of omega-6 and omega-3 essential fats is more favourable in quinoa than in other plant oils. An opportunity therefore exists to incorporate quinoa flour into more frequently consumed food products (e.g. biscuits) as an alternative means of increasing consumers omega-3 intake. The purpose of this study is to investigate the effect of consuming quinoa-enriched biscuits, compared to control, on markers of CVD risk over 4-weeks in older adults.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
40
2x15g biscuits per day for 28 consecutive days (4 weeks).
2x15g biscuits per day for 28 consecutive days (4 weeks).
Human Intervention Studies Unit, Ulster University
Coleraine, Londonderry, United Kingdom
Total cholesterol
Plasma cholesterol
Time frame: Change from baseline compared to control arm
Triglycerides
measured in plasma
Time frame: Change from baseline compared to control arm
LDL-cholesterol
measured in plasma
Time frame: Change from baseline compared to control arm
HDL-cholesterol
measured in plasma
Time frame: Change from baseline compared to control arm
total/HDL-cholesterol ratio
measured in plasma
Time frame: Change from baseline compared to control arm
Poly-unsaturated fatty acid status
measured in plasma
Time frame: Change from baseline compared to control arm
Antioxidant status
Ferric-reducing Ability Plasma
Time frame: Change from baseline compared to control arm
Inflammatory status
C-reactive protein
Time frame: Change from baseline compared to control arm
Blood pressure
Diastolic and systolic
Time frame: Change from baseline compared to control arm
Weight
Kg
Time frame: Change from baseline compared to control arm
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.